$IPHA News
Last published 1d ago
- 1d agoIPHAInnate Pharma to Host In-Person and Virtual Event on IPH4502 on November 18, 2026Business WireMARSEILLE, France--(BUSINESS WIRE)-- #Biotech--Innate Pharma to host in-person and virtual event on IPH4502 on November 18, 2026
- 6d agoIPHAInnate Pharma Q3 2026 Business Update and Financial Results - INNATE PHARMA SAEarnings Call TranscriptsHello, everyone. Thank you for joining us and welcome to the Innate Pharma third quarter 2026 business update and financial results. After today's prepared remarks, we will host a question and answer session. If you woul
- 2w agoIPHAPARIS:IPHInnate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027Business WirePACIFIC-9 Phase 3 trial led by AstraZeneca evaluates durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC Regulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA)
- 3w agoIPHAPARIS:IPHInnate Pharma to Participate in the Stifel Healthcare Conference and Jefferies Global Healthcare ConferenceBusiness WireRegulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that
- 3w agoIPHAPARIS:IPHInnate Pharma Announces Conference Call for Third Quarter 2026 Business and Financial UpdateBusiness WireRegulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announces that the Company will hold a conference call on Thursday, November 5, 2026, at 2 p.m. CET / 8
- 1mo agoIPHAInnate Pharma First Half 2026 Business Update and Financial Results - INNATE PHARMA SAEarnings Call TranscriptsHello, everyone. Thank you for joining us and welcome to the Innate Pharma first half 2026 business update and financial results. After today's prepared remarks, we will host a question and answer session. If you would l
- 1mo agoIPHAPARIS:IPHInnate Pharma Reports First Half 2026 Business Update and Financial ResultsBusiness WireNew strategic partnership with Sobi to advance lacutamab is effective, with a $75 million upfront payment; TELLOMAK-3 phase 3 initiated with FPI expected in Q1 2027 €30 million equity financing completed to
- 1mo agoIPHASobi and Innate announce partnership is now effective following completion of closing conditionsPR NewswireSwedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that ...
- 1mo agoIPHAPARIS:IPHInnate and Sobi Announce Partnership Is Now Effective Following Completion of Closing ConditionsBusiness WireThe partnership between Sobi and Innate is now effective, following expiration of the anti-trust waiting periods and completion of other conditions Transaction closing triggers the USD 75 million upfront payment
- 2mo agoIPHAPARIS:IPHInnate Pharma to Host Conference Call and Webcast on September 17 for First Half 2026 Financial Results and Business UpdateBusiness WireRegulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Thursday, September 17, 2026 at 2:00 p.m. CEST /
- 2mo agoIPHAPARIS:IPHInnate Pharma to Participate in the H.C. Wainwright 28th Annual Global Investment ConferenceBusiness WireRegulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that
- 2mo agoIPHAPARIS:IPHInnate Pharma Announces Conference Call and WebcastBusiness WireRegulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announces that the Company will hold a conference call on Friday, August 14, 2026 at 2:00 p.m. CEST / 8:00
- 3mo agoIPHASobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphomaPR NewswireSwedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that ...
- 3mo agoIPHASobi enters strategic partnership with Innate Pharma to license lacutamab in T-cell lymphomaPR NewswireSwedish Orphan Biovitrum AB (publ) (Sobi®) and Innate Pharma SA (Euronext Paris: IPH) (NASDAQ: IPHA) ("Innate" or the "Company") today announced that ...
- 3mo agoIPHAPARIS:IPHInnate Pharma to Advance Lacutamab Towards Phase 3 Following Partnership With Sobi and Appoints New Chief Medical OfficerBusiness WireInnate to advance lacutamab towards TELLOMAK-3 Phase 3 following the partnership with Sobi, a key step toward the filing for accelerated approval in Sézary syndrome Markus Jensen appointed Chief Medical Officer,
- 3mo agoIPHAPARIS:IPHInnate Pharma Enters Strategic Partnership With Sobi to License Lacutamab in T-cell LymphomaBusiness WireRegulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") and Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced that they have entered a strategic partnership to
- 3mo agoIPHAPARIS:IPHInnate Pharma to Participate in a Bladder Cancer Panel at the BTIG Virtual Biotechnology ConferenceBusiness WireRegulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that
- 3mo agoIPHAPARIS:IPHInnate Pharma Announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-drug Conjugate (ADC)Business WireEnrollment completed in the dose escalation of IPH4502-101 study, with preliminary data readout from 76 patients expected by year-end Favorable safety profile observed to date, with limited hematological
- 5mo agoGTBPIPHAINKTIPSCA Third Cancer Drug Just Entered the Clinic at an Under-$20-Million CompanyPR NewswireMost clinical-stage cancer companies with three drugs dosing patients in human trials carry valuations in the hundreds of millions, or more. GT...
- 5mo agoIPHAPARIS:IPHOutcome of Innate Pharma's 2026 Annual General MeetingBusiness WireRegulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") announced the voting results of its shareholders at the Annual General Meeting ("AGM"), which took place on May 21, 2026, in
- 5mo agoIPHAPARIS:IPHInnate Pharma to participate in the Jefferies Global Healthcare ConferenceBusiness WireRegulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its
- 5mo agoGTBPSMMTIDYAGSK+1B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters ClinicPR NewswireUSA News Group News Commentary — For more than two decades, B7-H3 sat on the shortlist of theoretically perfect cancer drug targets that nobody could ...
- 6mo agoIPHAInnate Pharma Q1 2026 Business Update and Financial ResultsINNATE PHARMA SAEarnings Call TranscriptsLadies and gentlemen, thank you for joining us and welcome to the N8 Pharma first quarter 2026 business update and financial results. After today's remarks, we will host a question and answer session. If you'd like to as
- 6mo agoIPHAPARIS:IPHInnate Pharma Reports First Quarter 2026 Business Update and Financial ResultsBusiness WireLacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) remains planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including pharma
- 6mo agoIPHAPARIS:IPHNumber of Shares and Voting Rights of Innate Pharma as of April 16, 2026Business WireRegulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation,
- 6mo agoIPHAPARIS:IPHInnate Pharma Announces Conference Call and Webcast for Q1 2026 Business UpdateBusiness WireRegulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announces that the Company will hold a conference call on Wednesday, May 13, 2026 at 1:30 p.m. CEST / 7:30 a.m. EDT, to
- 6mo agoIPHAPARIS:IPHInnate Pharma to Participate in the D. Boral Capital Global ConferenceBusiness WireRegulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its
- 6mo agoIPHAPARIS:IPHInnate Pharma to Present MATISSE Phase 2 Interim Results of IPH5201 in Clinical Trials Plenary Session at AACR 2026Business WireEncouraging early results catalyze continued investigation in the MATISSE Phase 2 study evaluating IPH5201, a first-in-class anti-CD39 monoclonal antibody, in combination with durvalumab and chemotherapy in resectable
- 7mo agoIPHAPARIS:IPHNumber of Shares and Voting Rights of Innate Pharma as of April 9, 2026Business WireRegulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation,
- 7mo agoIPHAPARIS:IPHInnate Pharma to Hold Its Annual General Meeting of Shareholders on May 21, 2026Business WireRegulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") will hold its Annual General Meeting of shareholders ("AGM") at 10:30 a.m. CEST on May 21, 2026, at its headquarters, 117 avenue
- 7mo agoIPHAPARIS:IPHInnate Pharma to Present at the AACR 2026 Oncology Industry Partnering EventBusiness WireRegulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), announced today that Yannis Morel, Chief Operating Officer, will present at the AACR Oncology Industry Partnering
- 7mo agoIPHAPARIS:IPHInnate Pharma to Participate in the Kempen Life Sciences ConferenceBusiness WireRegulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its
- 7mo agoIPHAPARIS:IPHInnate Pharma Files Its 2025 Universal Registration Document (Document D'enregistrement Universel) and 2025 Form 20-f Annual ReportBusiness WireRegulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced the filing of its 2025 Universal Registration Document (Document d'enregistrement universel) for the year ending
- 7mo agoIPHAInnate Pharma Full Year 2025INNATE PHARMA SAEarnings Call TranscriptsLadies and gentlemen, thank you for joining us and welcome to the Innate Pharma Full Year 2025 Earnings Call. After today's prepared remarks, we will host a question and answer session. If you would like to ask a questio
- 7mo agoIPHAPARIS:IPHInnate Pharma Reports Full Year 2025 Financial Results and Business UpdateBusiness WireLacutamab TELLOMAK-3 confirmatory Phase 3 trial in cutaneous T-cell lymphoma (CTCL) is planned for initiation in H2 2026, subject to non-dilutive financing options currently under negotiation, including pharma
- 7mo agoIPHAPARIS:IPHInnate Pharma Announces Conference Call and Webcast for Full Year 2025 Financial ResultsBusiness WireRegulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announces that the Company will hold a conference call on Thursday, March 26, 2026 at 2 p.m. CET / 9 a.m. EDT, following
- 8mo agoIPHAPARIS:IPHNumber of Shares and Voting Rights of Innate Pharma as of February 19, 2026Business WireRegulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation,
- 8mo agoIPHAPARIS:IPHInnate Pharma to Participate in the Leerink Partners Global Healthcare ConferenceBusiness WireRegulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, today announced that members of its
- 11mo agoIPHAPARIS:IPHInnate Pharma Releases Its 2026 Financial CalendarBusiness WireRegulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today released its 2026 financial calendar: March 26, 2026: Publication of 2025 financial statements May 13, 2026: Publication
- 11mo agoIPHAPARIS:IPHNumber of Shares and Voting Rights of Innate Pharma as of November 27, 2025Business WireRegulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation, Innate
- 12mo agoIPHAPARIS:IPHInnate Pharma to Present at Jefferies Global Healthcare ConferenceBusiness WireRegulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announces its participation in the Jefferies Global Healthcare Conference 2025. Members of its executive team will
- 1y agoIPHAPARIS:IPHInnate Pharma Announces FDA Clearance to Proceed With TELLOMAK 3, a Confirmatory Phase 3 Trial of Lacutamab in CTCLBusiness WireThe planned confirmatory Phase 3 trial, TELLOMAK 3, aims to demonstrate efficacy of lacutamab in patients with Sézary syndrome (SS) and Mycosis fungoides (MF), who failed at least one prior line of systemic
- 1y agoIPHAPARIS:IPHInnate Pharma Announces Conference Call and Webcast for Third Quarter 2025 Results and Business UpdatesBusiness WireRegulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that the Company will hold a conference call on Thursday, November 13, 2025, at 2 p.m. CET / 8 a.m. ET, to give an
- 1y agoIPHAPARIS:IPHInnate Pharma to Host Analyst and Investor Event on Lacutamab on October 28, 2025Business WireThe event will provide clinical perspectives and market outlook for lacutamab, Innate's lead proprietary product progressing towards potential accelerated approval in SS and confirmatory phase 3 initiation Leading
- 1y agoIPHAInnate Pharma S.A. (IPHA) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
- 1y agoIPHAPARIS:IPHInnate Pharma Reports First Half 2025 Business Update and Financial ResultsBusiness WireIPH4502 Nectin-4 ADC Phase 1 enrollment progressing well: Preclinical update and Trial In Progress presented at AACR Annual Meeting 2025 and ASCO 2025 Annual Meeting. Lacutamab BTD and Phase 3 preparation: FDA
- 1y agoIPHAPARIS:IPHInnate Pharma Announces Its Participation in the 25th Edition of the European Midcap EventBusiness WireRegulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company") today announced that Frédéric Lombard, Chief financial Officer of the Company, will participate in the 25th edition of the
- 1y agoIPHAPARIS:IPHInnate Pharma Announces Conference Call and Webcast for First Half 2025 Financial Results and Business UpdateBusiness WireRegulatory News: Innate Pharma SA (PARIS:IPH, NASDAQ:IPHA) ("Innate" or the "Company"), today announced that the Company will hold a conference call on Wednesday, September 17, 2025, at 2 p.m. CEST / 8 a.m. EDT, to
- 1y agoIPHAPARIS:IPHNumber of Shares and Voting Rights of Innate Pharma as of September 1, 2025Business WireRegulatory News: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation,
- 1y agoIPHAPARIS:IPHNumber of Shares and Voting Rights of Innate Pharma as of August 1, 2025Business WireRegulatory news: Pursuant to the article L. 233-8 II of the French "Code de Commerce" and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or "AMF") General Regulation,